


A Study of CLN-978, a CD19-directed T Cell Engager, in People with Rheumatoid Arthritis

Investigating a Potential New Treatment for Rheumatoid Arthritis

In this Phase 1 clinical trial, researchers are studying the **T cell engager, CLN-978**, as a potential treatment for people with active rheumatoid arthritis who have not responded well to at least two different types of treatments. This trial will take place in Europe.

The purpose of the study is to evaluate the safety, effects on the immune system, and effects on disease activity of CLN-978 in people living with rheumatoid arthritis. The trial will evaluate various doses of CLN-978.

What is a T Cell Engager?



In the body's immune system, there are special cells called T cells that find and destroy harmful cells.


B cells are another type of immune cell that usually help fight infections. Sometimes, B cells can make proteins that cause diseases like rheumatoid arthritis.

CLN-978 is a **T cell engager**. It works by guiding T cells to find B cells. Each CLN-978 molecule sticks to a T cell and a B cell, which makes the T cell destroy the B cell.

CLN-978 is investigational and has not been approved by any health authority. It is being studied in a clinical trial to see if it works for treating rheumatoid arthritis and is safe.

How is CLN-978 Given?

CLN-978 is given as an injection under the skin called a subcutaneous injection. This provides flexible and convenient dosing.



Who Can Participate in the Clinical Trial?

The trial will enroll eligible people in Europe who are aged 18 years or older and have:



at least moderately active
rheumatoid arthritis



not responded well to at least two disease
modifying anti-rheumatic medications that
have different ways of working



evidence of
B cell-driven disease

*Additional eligibility requirements will apply, and only a study doctor can determine eligibility to participate. For additional information, please see ClinicalTrials.gov ([NCT06994143](https://clinicaltrials.gov/ct2/show/study/NCT06994143)).

What Should Participants Expect?



Total participation time: Up to two years, after receiving the investigational therapy

Before treatment begins:

- Participants will attend one or more screening visits before the study treatment period begins.
- Certain tests and procedures will be done to make sure patients are eligible to participate in the study, such as blood sample collections and a physical exam.

Study treatment:

- Prior to CLN-978 treatment, two tissue biopsies will be done.
- Following a subcutaneous (under the skin) injection of CLN-978, participants will be monitored for two days in an inpatient setting, such as a hospital.

Post-treatment follow-up:

- Participants will attend eight follow-up visits to check on their health after receiving the investigational therapy (approximately one visit every one to two months).
- These visits will include procedures such as physical exams and blood sample collections. Four weeks after CLN-978 treatment is given, two tissue biopsies will be done.

Long-term follow-up (optional):

- There is an additional year-long follow-up period available to interested participants with four visits in total (one visit every three months).

CLN-978 Clinical Development Program

CLN-978 will be studied worldwide for the treatment of autoimmune diseases where B cells play an integral role:



Rheumatoid Arthritis:

Clinical trial sites are in Europe



Systemic Lupus Erythematosus:

Clinical trial sites are in the U.S., Europe, and Australia



Sjögren's Disease:

Clinical trial sites are in the U.S.

Contact

If you are interested in learning more about this clinical trial, please talk to your healthcare provider, visit [ClinicalTrials.gov \(NCT06994143\)](https://clinicaltrials.gov/ct2/show/study/NCT06994143), or scan the QR code.



CLN-978 is an investigational agent and has not been approved by the U.S. FDA or any other regulatory agency.

